Dasatinib, which has been used to treat CML and Ph+ ALL acute lymphoblastic leukemia (ALL), can also inhibit the Src family of kinases, including Lyn, which is often dysregulated in CLL B-cells. The gene discussed is SRC; the disease is acute lymphoblastic leukemia.